## Disclosures and Conflict of Interest (COI) Mitigation Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: Stephen Edge, MD, Carla Falkson, MBChB., M.Med., MD, Kimberly R. Gergelis, MD, Alissa Huston, MD, Sheheryar Kabraji, BMBCh, the staffs of the Empire State Hematology and Oncology Society and Physicians' Education Resource®, LLC.

| Faculty              | Grant/Research<br>Support                              | Consultant  | Speakers'<br>Bureau | Shareholder | Other   |
|----------------------|--|---|---------------------|-------------|---|
| Seth Wander, MD, PhD | Genentech, Eli<br>Lilly, Pfizer, Regor<br>Therapeutics | Foundation Medicine,<br>Novartis, AstraZeneca,<br>Eli Lilly   |                     |             | Advisory Board: Pfizer, Biovica, Hologic, Puma Biotechnology  Speaking/Education: Guardant Health, 2ndMD, Eli Lilly   |
| Shipra Gandhi, MD    |  | Astrazeneca, MedPage<br>Today   |                     |             | Honoraria: Hologic,<br>Novartis, OncLiv,<br>Aptitude Health   |
| Anna Weiss, MD       |  | Merck, Myriad, Abbvie   |                     |             | Advisory Board: Merck,<br>Myriad, Abbvie  |
| Ruth O'Regan, MD     | Puma, Novartis   | AstraZeneca, Pfizer, Genomic Health, Biotheranostics, Novartis,, Lilly, Puma Biotechnology, Genentech, Immunomedics,, MacroGenics |                     |             | Advisory Committee: Pfizer, Lilly, Puma, Biotechnology Novartis, Seagen, AstraZeneca  Data and Safety Monitoring Board/Committee: CRITERIUM, Immunomedics, Gilead |
| Susan Dent, MD       |  | Novartis, Pfizer, Gilead<br>Sciences, AstraZeneca,<br>Hoffman<br>LaRoche/Genentech,<br>Myocardial Solutions,<br>Inc.              |                     |             |   |

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.